[1]曾祥斌,邓嘉奇,张鹏飞,等.干扰素γ与沐舒坦联合雾化吸入治疗慢性支气管炎急性发作的临床疗效[J].医学信息,2024,37(20):123-126.[doi:10.3969/j.issn.1006-1959.2024.20.025]
　ZENG Xiangbin,DENG Jiaqi,ZHANG Pengfei,et al.Clinical Effect of Combined Interferon γ and Mucosolvan Aerosol Inhalation in the Treatment of Acute Attack of Chronic Bronchitis[J].Journal of Medical Information,2024,37(20):123-126.[doi:10.3969/j.issn.1006-1959.2024.20.025]
点击复制

干扰素γ与沐舒坦联合雾化吸入治疗慢性支气管炎急性发作的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
123-126
栏目:
论著
出版日期:
2024-10-15

文章信息/Info

Title:
Clinical Effect of Combined Interferon γ and Mucosolvan Aerosol Inhalation in the Treatment of Acute Attack of Chronic Bronchitis
文章编号:
1006-1959（2024）20-0123-04
作者:
曾祥斌; 邓嘉奇; 张鹏飞; 曾丽丽; 吴 丹
吉水县人民医院呼吸内科，江西 吉水 331600
Author(s):
ZENG Xiangbin; DENG Jiaqi; ZHANG Pengfei; ZENG Lili; WU Dan
Department of Respiratory Medicine,Jishui County People’s Hospital,Jishui 331600,Jiangxi,China
关键词:
干扰素γ; 沐舒坦; 雾化吸入; 慢性支气管炎; 急性发作
Keywords:
Interferon γ; Mucosolvan; Atomization inhalation; Chronic bronchitis; Acute attack
分类号:
R562
DOI:
10.3969/j.issn.1006-1959.2024.20.025
摘要:
目的 研究联合干扰素γ与沐舒坦雾化吸入治疗慢性支气管炎急性发作的临床疗效。方法 选取2021年1月-2023年3月我院诊治的61例慢性支气管炎急性发作患者为研究对象，采用随机数字表法分为对照组（n=31）和观察组（n=30）。对照组采用干扰素γ治疗，观察组在对照组基础上联合给予沐舒坦雾化吸入治疗，比较两组临床疗效、临床症状改善时间、肺功能指标[呼气峰流速（PEF）、肺活量（FVC）、第1秒最大呼气量（FEV1）]、不良反应发生率。结果 观察组治疗总有效率为96.67%，高于对照组的83.87%（P＜0.05）；观察组咳嗽、咳痰、喘息消失时间均短于对照组（P＜0.05）；两组治疗后PEF、FVC、FEV1均高于治疗前，且观察组高于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 联合干扰素γ与沐舒坦雾化吸入治疗急性发作慢性支气管炎的临床疗效确切，可促进临床症状消退，改善肺功能，且不良反应发生率低，是一种可行、有效的治疗方案。
Abstract:
Objective To study the clinical efficacy of combined interferon γ and mucosolvan aerosol inhalation in the treatment of acute exacerbation of chronic bronchitis.Methods A total of 61 patients with acute exacerbation of chronic bronchitis diagnosed and treated in our hospital from January 2021 to March 2023 were selected as the research objects. They were divided into control group (n=31) and observation group (n=30) by random number table method. The control group was treated with interferon γ, and the observation group was treated with mucosolvan aerosol inhalation on the basis of the control group. The clinical efficacy, improvement time of clinical symptoms, pulmonary function indexes [peak expiratory flow (PEF), vital capacity (FVC), maximum expiratory volume in the first second (FEV1)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.67%, which was higher than 83.87% in the control group (P<0.05). The disappearance time of cough, sputum and wheezing in the observation group was shorter than that in the control group (P<0.05). After treatment, PEF, FVC and FEV1 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion The combination of interferon γ and mucosolvan aerosol inhalation has a definite clinical effect in the treatment of acute exacerbation of chronic bronchitis, which can promote the regression of clinical symptoms, improve lung function, and has a low incidence of adverse reactions. It is a feasible and effective treatment plan.

参考文献/References:

[1]黄利民,张炜,孙兆瑞,等.氨溴索雾化吸入治疗老年慢性支气管炎疗效及安全性的系统评价[J].东南国防医药,2020,22(2):165-171. [2]Grotheer M,Schulz B.Feline asthma and chronic bronchitis-an overview of diagnostics and therapy[J].Tierarztl Prax Ausg K Kleintiere Heimtiere,2019,47(3):175-187.[3]高彩艳.定喘汤联合沐舒坦治疗痰热郁肺中老年慢性支气管炎急性发作临床观察[J].光明中医,2019,34(10):1584-1585,1607.[4]田言辉,姚俊,曾圣凯,等.联合干扰素γ和沐舒坦雾化吸入治疗慢性支气管炎急性发作的价值研究[J].湖南师范大学学报(医学版),2015,12(2):96-98. [5]赵进文.盐酸氨溴索雾化吸入治疗老年慢性支气管炎的作用探究[J].甘肃科技,2019,35(7):131-132,103.[6]刘振荣,王晓燕.沐舒坦雾化吸入治疗小儿肺炎82例[J].第四军医大学学报,2004,25(14):1280.[7]杨世伟.氨茶碱联合盐酸氨溴索治疗支气管哮喘患儿的效果观察[J].河南医学研究,2018,27(14):2620-2621.[8]彭思萃,吴建谷.盐酸氨溴索联合氨茶碱治疗小儿支气管哮喘的效果及对肺功能的影响[J].中国医药科学,2016(2):69-71.[9]陈兰燕.莫西沙星与盐酸氨溴索联合应用对慢性支气管炎的疗效及安全性探究[J].黑龙江医学,2017,41(3):273-274.[10]魏广清,谢琳.布地奈德福莫特罗粉吸入剂联合异丙托溴铵溶液雾化吸入治疗 老年喘息型慢性支气管炎的效果[J].河南医学研究,2019,28(3):480-481.[11]王海燕.沐舒坦联合多索茶碱对老年慢性支气管炎急性发作患者血清C反应蛋白、白细胞介素-6、肿瘤坏死因子-α 水平的影响[J].中国老年学杂志,2017,37(2):413-414.[12]王青利,刘晓娥.干扰素α1b联合氨溴索雾化吸入治疗婴幼儿喘息性疾病93例[J].陕西医学杂志,2016,45(10):1418-1419.[13]张艳丽.干扰素γ联合盐酸氨溴索注射液雾化吸入对慢性支气管炎急性发作患者体征改善及生活质量的影响[J].哈尔滨医药,2018,38(1):10-11.[14]潘冬梅.沐舒坦雾化吸入联合静脉注射治疗新生儿肺炎的疗效观察[J].医学信息,2017,30(15):99-100.[15]贾东岩,王志刚,李亚光,等.沐舒坦雾化吸入联合静脉注射治疗脑卒中伴坠积性肺炎的疗效[J].中国老年学杂志,2012,32(17):3804-3805.[16]张壮丽.干扰素γ联合沐舒坦雾化吸入治疗慢性支气管炎急性发作的效果观察[J].河南医学研究,2015,24(12):115-116.[17]于海翔,韩春山,韩志峰,等.合并 COPD 的老年食管癌患者围术期应用不同剂量沐舒坦的疗效[J].中国老年学杂志,2016,36(15):3767-3768.[18]戴武强.盐酸氨溴索治疗慢性支气管炎急性发作的应用价值[J].中国处方药,2018,16(4):78-79.[19]李国庆,张丽莉.沐舒坦雾化吸入治疗老年慢性支气管炎急性发作临床效果分析[J].基层医学论坛,2018,22(4):502-503

相似文献/References:

[1]高凤霞.沐舒坦雾化吸入联合静脉注射治疗新生儿肺炎的效果分析[J].医学信息,2018,31(04):12.[doi:10.3969/j.issn.1006-1959.2018.04.005]
　GAO Feng-xia.Effect of Atomization Inhalation of Ambroxol Combined with Intravenous Injection in the Treatment of Neonatal Pneumonia[J].Journal of Medical Information,2018,31(20):12.[doi:10.3969/j.issn.1006-1959.2018.04.005]
[2]李凤利,陈 伟,张 林.不同剂量沐舒坦在肺癌围术期的肺功能保护作用[J].医学信息,2018,31(07):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]
　LI Feng-li,CHEN Wei,ZHANG Lin.Protective Effects of Different Doses of Ambroxol on Lung Function in Patients with Lung Cancer during Perioperative Period[J].Journal of Medical Information,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]

更新日期/Last Update: 1900-01-01